These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of ivermectin and diethylcarbamazine on microfilariae and overall microfilaria production in bancroftian filariasis. Stolk WA, VAN Oortmarssen GJ, Pani SP, DE Vlas SJ, Subramanian S, DAS PK, Habbema JD. Am J Trop Med Hyg; 2005 Nov; 73(5):881-7. PubMed ID: 16282298 [Abstract] [Full Text] [Related]
7. The role of albendazole in programmes to eliminate lymphatic filariasis. Ottesen EA, Ismail MM, Horton J. Parasitol Today; 1999 Sep; 15(9):382-6. PubMed ID: 10461168 [Abstract] [Full Text] [Related]
8. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Bockarie MJ, Alexander ND, Hyun P, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW. Lancet; 1998 Jan 17; 351(9097):162-8. PubMed ID: 9449870 [Abstract] [Full Text] [Related]
9. Tolerability and efficacy of single dose diethylcarbamazine (DEC) alone or co-administration with Ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, South India. Pani SP, Reddy GS, Vanamail P, Venkatesvarlou N, Das LK, Vijayan AP. J Commun Dis; 2004 Dec 17; 36(4):240-50. PubMed ID: 16506546 [Abstract] [Full Text] [Related]
10. Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. Hoti SL, Pani SP, Vanamail P, Athisaya Mary K, Das LK, Das PK. Natl Med J India; 2010 Dec 17; 23(2):72-6. PubMed ID: 20925201 [Abstract] [Full Text] [Related]
13. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, Raju HKK, Rahi M, Somani RK, Suryaprakash MK, Dwivedi GP, Weil GJ. PLoS Negl Trop Dis; 2021 Feb 17; 15(2):e0009069. PubMed ID: 33591979 [Abstract] [Full Text] [Related]
14. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. Edi C, Bjerum CM, Ouattara AF, Chhonker YS, Penali LK, Méité A, Koudou BG, Weil GJ, King CL, Murry DJ. PLoS Negl Trop Dis; 2019 May 17; 13(5):e0007325. PubMed ID: 31107869 [Abstract] [Full Text] [Related]
16. How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis? Kura K, Stolk WA, Basáñez MG, Collyer BS, de Vlas SJ, Diggle PJ, Gass K, Graham M, Hollingsworth TD, King JD, Krentel A, Anderson RM, Coffeng LE. Clin Infect Dis; 2024 Apr 25; 78(Supplement_2):S93-S100. PubMed ID: 38662701 [Abstract] [Full Text] [Related]
17. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators. Jambulingam P, Subramanian S, de Vlas SJ, Vinubala C, Stolk WA. Parasit Vectors; 2016 Sep 13; 9(1):501. PubMed ID: 27624157 [Abstract] [Full Text] [Related]